An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A recent report found that prescriptions for GLP-1 drugs — the class that includes popular medicines like Ozempic and Wegovy — are increasing faster among adults with serious mental illness than in the general population. The story comes from prescribers and prescription data, not a single clinical trial, and it highlights a trend rather than proving cause and effect. GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1 (GLP-1) that helps control appetite and blood sugar. In everyday terms, these medicines make you feel fuller and can slow how quickly food leaves your stomach, which often leads to weight loss and lower blood sugar. Doctors use them primarily for type 2 diabetes and, more recently, for obesity treatment. People often know brand names like Ozempic or Wegovy, but the important part is the drug class and what it does in the body. The report looked at prescription patterns and found that adults diagnosed with serious mental illnesses — conditions such as schizophrenia, bipolar disorder, or major depressive disorder with significant impairment — are getting these drugs at a faster rate than people without those diagnoses. This is an observational finding about prescriptions written and filled. It doesn’t tell us whether the drugs are more effective or riskier in this group, nor does it show why prescribers are choosing them more often. The size of the increase and the exact numbers will depend on the dataset the reporters used, which the snippet doesn’t spell out, so we should be cautious about sweeping conclusions. This matters because people with serious mental illness often have higher rates of obesity, diabetes, and cardiovascular risk. Weight gain can be driven by factors including lifestyle, social determinants, and some psychiatric medications. If GLP-1 drugs are being used more in this population, it could mean clinicians are trying to address those physical health needs. For patients, caregivers, and mental health clinicians, this trend could signal increased attention to metabolic health in psychiatric care. But there are important caveats. The report is about prescribing trends, not confirmed benefits or harms in this specific group. People with serious mental illness were often excluded or underrepresented in the major GLP-1 clinical trials, so we don’t have as much high-quality evidence about safety and long-term effects for them. These drugs can cause side effects like nausea, digestive upset, and in rare cases more serious problems. They also cost a lot and may not be covered by all insurance plans for people without diabetes. Finally, the fact that prescriptions are rising doesn’t guarantee appropriate use; it could reflect off-label prescribing, patient demand, or other system factors. Bottom line: More people with serious mental illness are being prescribed GLP-1 drugs, which could help address weight and diabetes risk, but this is a prescribing trend rather than proof those drugs are safe or more effective for this group.
Source: MedPage Today